Evidence map›Paper›PMID 21493739›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2011

Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial.

Trevor J Wilkieson, Alistair J Ingram, Mark A Crowther, Steven D Soroka, Ryuta Nagai, Kailash K Jindal, Catherine M Clase

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Strategies to Prevent Hemodialysis Catheter Dysfunction.Journal of the American Society of Nephrology : JASN · 2025
    Review
  5. A Comprehensive Review of Catheter-Related Thrombosis.Journal of clinical medicine · 2024
    Review
  6. Thrombosis and anticoagulation in the setting of renal or liver disease.Hematology. American Society of Hematology. Education Program · 2016
    Review
  7. Article
  8. Article
  9. American Society of Nephrology Quiz and Questionnaire 2013: RRT.Clinical journal of the American Society of Nephrology : CJASN · 2014
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Trevor J WilkiesonDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Alistair J Ingram
Mark A Crowther
Steven D Soroka
Ryuta Nagai
Kailash K Jindal
Catherine M Clase

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

BACKGROUND AND

objectivesTo determine whether warfarin prolongs the time to first mechanical-catheter failure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a multicenter parallel-group randomized controlled trial with blinding of participants, trial staff, clinical staff, outcome assessors, and data analysts. Randomization was in a 1:1 ratio in blocks of four and was concealed by use of fax to a central pharmacy. Hemodialysis patients with newly-placed catheters received low-intensity monitored-dose warfarin, target international normalized ratio (INR) 1.5 to 1.9, or placebo, adjusted according to schedule of sham INR results. The primary outcome was time to first mechanical-catheter failure (inability to establish a circuit or blood flow less than 200 ml/min).

resultsWe randomized 174 patients: 87 to warfarin and 87 to placebo. Warfarin was associated with a hazard ratio (HR) of 0.90 (P=0.60; 95% confidence interval [CI], 0.57, 1.38) for time to first mechanical-catheter failure. Secondary analyses were: time to first guidewire exchange or catheter removal for mechanical failure (HR 0.78; 95% CI, 0.37, 1.6); time to catheter removal for mechanical failure (HR 0.67; 95% CI, 0.19, 2.37); and time to catheter removal for any cause (HR 0.89; 95% CI, 0.42, 1.81). Major bleeding occurred in 10 participants assigned to warfarin and seven on placebo (relative risk, 1.43; 95% CI, 0.57, 3.58; P=0.61).

conclusionsWe found no evidence for efficacy of low-intensity, monitored-dose warfarin in preventing mechanical-catheter failure.

Indexed as

AgedAnticoagulantsCatheterization, Central VenousDose-Response Relationship, DrugFemaleHumansInternational Normalized RatioKaplan-Meier EstimateKidney Failure, ChronicMaleMiddle AgedPlacebosRenal DialysisTreatment OutcomeUpper Extremity Deep Vein ThrombosisWarfarinAnticoagulantsPlacebosWarfarin

Identifiers

PMID21493739
PMCPMC3087766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.